- Systemic medications used in treatment of common dermatological conditions: Safety profile with respect to pregnancy, breast feeding and content in seminal fluid. [Journal Article]
- JDJ Dermatolog Treat 2017 Jan 16; :1-53
- CONCLUSIONS: We have provided detailed evidence about the safety profile for the use of systemic medication used in the treatment of common dermatological conditions, such as atopic dermatitis, psoriasis and acne with respect to pregnancy, breastfeeding and spermatogenesis. The following medications are completely contraindicated in pregnancy: retinoids, methotrexate, mycophenolate and fumaric acid esters, whilst ciclosporin and hydroxychloroquine are considered safer options. Azathioprine and biologics have been considered on a case by case scenario. There is an association with impaired neonatal immunity and a possible VACTERL association with biologics. There is insufficient evidence to recommend ustekinumab. Dapsone should also be considered on a case by case basis as it is associated with haemolysis and hyperbilirubinaemia in the neonate. The following medications are contraindicated in breastfeeding: retinoids, methotrexate, mycophenolate, fumaric acid esters and ciclosporin. There is conflicting information about the use of azathioprine. Dapsone use during breastfeeding is associated with haemolysis and hyperbilirubinaemia in the neonate. The use of hydroxychloroquine is felt to be safe. The data associated with the use of biologic agents is limited, specific guidance for each biological medication is detailed in the relevant section. Methotrexate is completely contraindicated in male patients actively trying for children and needs to be suspended for at least 3 months prior to contraception. The following medications are felt to be low risk: biologics, ciclopsorin and retinoids, there are some concerns however regarding isotretinoin use in males when their female partner is already pregnant and recent advice recommends contraception. There is insufficient information regarding the use of mycophenolate, fumaric acid esters, azathioprine, hydroxychloroquine, dapsone and ustekinumab in order to consider their safety profile.
- Severe antiphospholipid antibody syndrome - response to plasmapheresis and rituximab. [Journal Article]
- JDJ Dermatolog Treat 2017 Jan 13; :1-8
- Antiphospholipid antibody syndrome is a systemic autoimmune disease characterized by arterial and/or venous thrombosis, recurrent abortions and detection of antiphospholipid antibodies. In fulminant ...
Antiphospholipid antibody syndrome is a systemic autoimmune disease characterized by arterial and/or venous thrombosis, recurrent abortions and detection of antiphospholipid antibodies. In fulminant cases involvement of multiple organs can lead to significant morbidity and even fatal outcomes, so that a rash, interdisciplinary treatment is needed. Here, we describe the case of a 39 year-old woman with a severe hard-to-treat antiphospholipid antibody syndrome with arterial occlusion and progressive skin necrosis who was successfully treated with a combination therapy with plasmapheresis and rituximab. The treatment led to complete remission of the skin lesions for over a year. Clinical response correlated with a long-lasting reduction of antiphospholipid antibodies and B-cell depletion. This case demonstrates the use of antiphospholipid antibodies for monitoring APS-activity and shows that this severe vascular disease requires rigorous therapeutic approaches.
- Oral propranolol for infantile hemangiomas: a prospective study on the role of 48-hour Holter monitoring in additional safety assessment. [Journal Article]
- JDJ Dermatolog Treat 2017 Jan 11; :1-8
- CONCLUSIONS: Oral propranolol for IHs does not remarkably affect heart rhythm including circadian variations throughout hospital initiation. Therefore, there is no necessity for Holter monitoring in additional safety assessment.
- Dietary modifications in atopic dermatitis: patient-reported outcomes. [Journal Article]
- JDJ Dermatolog Treat 2017 Jan 03; :1-29
- CONCLUSIONS: Since dietary modifications are extremely common, the role of diet in AD and potential nutritional benefits and risks need to be properly discussed with patients.
- The Pulsed Dye Laser is more effective and rapidly acting than Intralesional Meglumine Antimoniate Therapy for cutaneous Leishmaniasis. [Journal Article]
- JDJ Dermatolog Treat 2017 Jan 03; :1-15
- CONCLUSIONS: The PDL can cure many cases of CL particularly in their early stages faster than MA.
- The Promising Potential Role of Ketones in Inflammatory Dermatologic Disease: A New Frontier in Treatment Research. [Journal Article]
- JDJ Dermatolog Treat 2017 Jan 03; :1-16
- The ketogenic diet has been shown to be beneficial for numerous diseases across different organ systems, but a dearth of information exists regarding these benefits for skin disease. Here, we searche...
The ketogenic diet has been shown to be beneficial for numerous diseases across different organ systems, but a dearth of information exists regarding these benefits for skin disease. Here, we searched the literature for known mechanisms behind inflammation in dermatologic disease and correlated that with suggested mechanisms of anti-inflammatory activity of ketones and a ketogenic state in the human body to observe how ketones and ketosis might aid in the treatment of inflammatory skin diseases based on these mechanisms. Specifically, we found that ketones modulate the NRPL3 inflammasome, augment anti-oxidation against reactive oxygen species through various direct and indirect means, and may influence mTOR activity, which are all involved in inflammatory dermatologic diseases to an extent. This evidence shows that ketones and the ketogenic diet may have a promising role in the dermatologist's disease treatment repertoire. Our goal is to provide a novel direction for research in the role of a ketogenic diet and even exogenous ketone therapy in the treatment of inflammatory dermatologic disease.
- The Impact of PASI 75 and PASI 90 on Quality of Life in Moderate to Severe Psoriasis Patients. [Journal Article]
- JDJ Dermatolog Treat 2016 Dec 31; :1-16
- CONCLUSIONS: There has been tremendous attention surrounding newer biologic agents that can achieve PASI 90 and even PASI 100. Although the results are impressive with regard to physical improvement of psoriasis, there may not be a clinically significant difference in QoL when comparing patients who achieve PASI-75 versus PASI 90.
- Combined therapy in vulvar lichen sclerosus: does topical tretinoin improve the efficacy of mometasone furoate? [Journal Article]
- JDJ Dermatolog Treat 2017 Jan 08; :1-8
- CONCLUSIONS: The combination with a topical retinoid did not enhance the effectiveness of a potent corticosteroid in the treatment of VLS. Either the scarce efficacy of the short-contact therapy regimen or a less favorable safety profile of such combination may account for these findings.
- Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: A review of literature. [Journal Article]
- JDJ Dermatolog Treat 2016 Dec 26; :1-32
- Janus kinase family (JAKs) has recently attracted the attention of many researchers, and several JAK inhibitor drugs have been developed targeting different members of the JAK family. Tofacitinib and...
Janus kinase family (JAKs) has recently attracted the attention of many researchers, and several JAK inhibitor drugs have been developed targeting different members of the JAK family. Tofacitinib and ruxolitinib are U.S. FDA approved drugs in this family approved for rheumatoid arthritis and myeloproliferative diseases, respectively. Dysregulation of JAK/STAT pathway is also involved in many skin diseases, specifically inflammatory disorders. We overview the JAK/STAT signaling pathway and its involvement in skin diseases. We also review clinical studies of JAK inhibitors in field of dermatology, including psoriasis, atopic dermatitis, alopecia areata and vitiligo. Although the available evidence shows promising results, it is still too early draw a firm conclusion about the place of these drugs in dermatological treatment.
New Search Next
- Prevalence of weight loss attempts and behaviors used by individuals with psoriasis in the United States population. [Journal Article]
- JDJ Dermatolog Treat 2016 Dec 26; :1-19
- CONCLUSIONS: Participants self-reporting psoriasis were less likely to use exercise to lose weight. Clinicians should identify physical activity barriers among overweight/obese psoriasis patients, especially among those attempting to reduce weight.